Longitudinal analysis of serum microRNAs as predictors of cirrhosis regression during treatment of hepatitis B virus infection

MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis

(2018) Jorge Matias Caviglia et al.   HEPATOLOGY

Is miR-21 a potent target for liver fibrosis?

(2018) Sanchuan Lai et al.   HEPATOLOGY

Global microRNA expression profiling in the liver biopsies of hepatitis B virus-infected patients suggests specific microRNA signatures for viral persistence and hepatocellular injury

(2018) Avishek Kumar Singh et al.   HEPATOLOGY

Serum MicroRNA Levels as a Noninvasive Diagnostic Biomarker for the Early Diagnosis of Hepatitis B Virus-Related Liver Fibrosis

(2017) Suxia Bao et al.   Gut and Liver

Plasma MicroRNA Levels Are Associated With Hepatitis B e Antigen Status and Treatment Response in Chronic Hepatitis B Patients

(2017) Meike H. van der Ree et al.   JOURNAL OF INFECTIOUS DISEASES

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

(2017) Meike H van der Ree et al.   LANCET

Global and immunotherapeutic insights into hepatitis B

(2017) Mala K. Maini et al.   Nature Reviews Gastroenterology & Hepatology

Circulating microRNAs: Possible role as non-invasive diagnostic biomarkers in liver disease

(2017) Kishor Pant et al.   Clinics and Research in Hepatology and Gastroenterology

MicroRNA-421 induces hepatic mitochondrial dysfunction in non-alcoholic fatty liver disease mice by inhibiting sirtuin 3

(2016) Yang Cheng et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C

(2016) Kentaro Matsuura et al.   HEPATOLOGY

Data Normalization Strategies for MicroRNA Quantification

(2015) H. Schwarzenbach et al.   CLINICAL CHEMISTRY

Identification of Endogenous Controls for Analyzing Serum Exosomal miRNA in Patients with Hepatitis B or Hepatocellular Carcinoma

(2015) Yi Li et al.   DISEASE MARKERS

Hepatic inflammation and fibrosis: Functional links and key pathways

(2015) Ekihiro Seki et al.   HEPATOLOGY

Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012

(2015) Henry Roberts et al.   HEPATOLOGY

Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate

(2015) G. Papatheodoridis et al.   JOURNAL OF VIRAL HEPATITIS

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

(2015) Aparna Schweitzer et al.   LANCET

The human miRNA repertoire of different blood compounds

(2014) Petra Leidinger et al.   BMC GENOMICS

Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus

(2014) G. Dultz et al.   JOURNAL OF VIRAL HEPATITIS

Hepatitis C virus and microRNAs: miRed in a host of possibilities

(2014) Ragunath Singaravelu et al.   Current Opinion in Virology

Translating an Understanding of the Pathogenesis of Hepatic Fibrosis to Novel Therapies

(2013) Don C. Rockey   Clinical Gastroenterology and Hepatology

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

(2012) Patrick Marcellin et al.   LANCET

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

(2010) Ting-Tsung Chang et al.   HEPATOLOGY